Bumetanide prevents diazepam-modified anxiety-like behavior in lipopolysaccharide-treated mice

Eur J Pharmacol. 2021 Aug 5:904:174195. doi: 10.1016/j.ejphar.2021.174195. Epub 2021 May 15.

Abstract

Benzodiazepine receptor agonists are widely prescribed therapeutic agents that alter gamma-aminobutyric acid (GABA)A receptor activity and have anxiolytic effects. Post-operative use of benzodiazepines is a risk factor of delirium. Inflammatory conditions alter the anxiolytic effects of benzodiazepine. We investigated the effect of diazepam, a typical benzodiazepine anxiolytic, on changes in the emotional behavior of mice in a hole-board test after lipopolysaccharide (LPS) treatment. Diazepam dose-dependently increased the number of head-dips at doses that did not alter locomotor activity; however, diazepam dose-dependently significantly decreased the number of head-dips at doses that did not alter locomotor activity in LPS-treated mice. Flumazenil, a benzodiazepine receptor antagonist, normalized the decrease in head-dipping behavior caused by diazepam treatment in normal and LPS-treated mice. The decrease of the head-dipping effect caused by diazepam was attenuated by minocycline in LPS-treated mice. We further found that the decrease in head-dipping behavior caused by diazepam was blocked by bumetanide, a Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) antagonist, in LPS-treated mice. These findings suggest that diazepam induces the anxiety-like behavior under inflammation conditions, and may cause the GABAA receptor dysfunction associated with the chloride plasticity mediated by NKCC1, which contributes to benzodiazepine-induced delirium after surgery.

Keywords: Anxiety; Bumetanide; Diazepam; Inflammation; Lipopolysaccharide; NKCC1.

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Anti-Anxiety Agents / toxicity
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Anxiety / prevention & control*
  • Behavior, Animal / drug effects
  • Bicuculline / pharmacology
  • Bicuculline / therapeutic use
  • Bumetanide / pharmacology*
  • Bumetanide / therapeutic use
  • Diazepam / pharmacology*
  • Diazepam / toxicity
  • Emotions / drug effects
  • Flumazenil / pharmacology
  • Flumazenil / therapeutic use
  • GABA-A Receptor Agonists / adverse effects
  • GABA-A Receptor Agonists / pharmacology*
  • GABA-A Receptor Antagonists / pharmacology
  • GABA-A Receptor Antagonists / therapeutic use
  • Inflammation / chemically induced
  • Inflammation / complications
  • Lipopolysaccharides / toxicity
  • Male
  • Mice
  • Mice, Inbred ICR
  • Minocycline / pharmacology
  • Minocycline / therapeutic use
  • Motor Activity / drug effects
  • Sodium Potassium Chloride Symporter Inhibitors / pharmacology*
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use

Substances

  • Anti-Anxiety Agents
  • Anti-Bacterial Agents
  • GABA-A Receptor Agonists
  • GABA-A Receptor Antagonists
  • Lipopolysaccharides
  • Sodium Potassium Chloride Symporter Inhibitors
  • Bumetanide
  • Flumazenil
  • Minocycline
  • Diazepam
  • Bicuculline